Telormedix Granted European Patent for Vesimune

BIOGGIO, Switzerland

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, announced today that it has been granted the European Patent No. 2393474 entitled “Pharmaceutical compositions comprising imidazoquinolin (amines) and derivatives thereof suitable for local administration” by the European Patent Office. The European patent, which will expire in 2030, broadly covers Telormedix’s lead product Vesimune (TMX-101) and its use for the treatment of bladder cancer. Further patents for Telormedix’s Vesimune have also recently been granted in China and Australia.

Vesimune is Telormedix’s lead product, a TLR-7 agonist currently has successfully completed a Phase II trial in CIS (carcinoma in situ) of the bladder. The product is a unique sterile liquid formulation of a marketed immune modulatory compound, designed on innovative technology principles to carrier drug delivery systems in order to increase solubility, bio-adhesiveness and stability. These properties mean that the product can be used in therapeutic settings that the original product could not.

Dr Johanna Holldack, CEO of Telormedix, commented: “This patent is the single most important patent for Vesimune, our lead compound for the treatment of bladder cancer. With our recent positive Phase II results, this patent puts us in a strong position for partnering discussions.”

– Ends –

Notes for editors:

About Vesimune

Telormedix’s lead product, Vesimune (TMX-101), is a targeted small molecule for the treatment of superficial bladder cancer. The active ingredient in Vesimune is a known immunomodulatory molecule with a favorable safety profile and a demonstrated clinical efficacy in oncological and viral diseases. The Company expects that this targeted therapy will have an improved safety and efficacy profile in comparison to standard of care. Telormedix has taken advantage of existing regulatory data and clinical experience in order to bring Vesimune quickly through Phase I/II clinical trials.

About Telormedix

Telormedix (www.telormedix.com), founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and infectious diseases. The Company’s lead product, Vesimune (TMX-101), has just successfully completed a Phase II clinical trial for the treatment of CIS (carcinoma in situ) of the bladder. In addition, Telormedix is developing two additional TLR7-targeted molecules, TMX-201 and TMX-202 both of which would make good vaccine adjuvants. As these molecules have substantially improved pharmacokinetics and pharmacodynamics profiles they have the potential to fully realise the anticancer promise of TLR 7 agonists. One of these molecules, TMX-202 has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. The candidate has already successfully completed a number of in vivo studies.

Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists, Aravis (Zurich, Switzerland) and Proquest Investments (Florida, USA).